(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) **World Intellectual Property Organization**
International Bureau

(43) **International Publication Date**
4 July 2013 (04.07.2013)

(10) **International Publication Number**
WO 2013/102209 Al

(51) **International Patent Classification:**
A61K 38/17 (2006.01)

(21) **International Application Number:**
PCT/US20 12/0723 10

(22) **International Filing Date:**
3 1 December 2012 (3 1.12.2012)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
61/581,836 30 December 201 1 (30. 12.201 1) US

(71) **Applicant: JOSLIN DIABETES CENTER, INC.** [US/US]; One Joslin Place, Boston, Massachusetts 02215 (US).

(72) **Inventors: USSAR, Siegfried;** 400 Brookline Avenue, Apt 22E, Boston, Massachusetts 02215 (US). **KAHN, C. Ron¬ ald;** 64 Valentine Park, West Newton, Massachusetts 02465 (US).

(74) **Agents: WILSON, David J.** et al; Pierce Atwood LLP, 100 Summer Street, Suite 2250, Boston, Massachusetts 021 10 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available):* AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available):* ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on nextpage]

(54) **Title:** GLYPICAN-4 BASED COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INSULIN RESISTANCE



(57) **Abstract:** Provided herein are methods for increasing insulin sensitivity in a subject. A method may comprise administering to a subject in need of increased insulin sensitivity a therapeutically effective amount of a glypican-4 agent. Also provided herein are methods for determining whether a subject is or is likely to become insulin resistant. A method may comprise determining the level of glypican-4 in a subject, wherein an elevated level of glypican-4 indicates that a subject is or is likely to become insulin resistant.

WO 2013/102209 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

GLYPICAN-4 BASED COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INSULIN RESISTANCE

5

GOVERNMENT SUPPORT

10 This invention was made with government support under grant Nos. DK3 1036, DK82654 and DK36836 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND

15 Obesity is the main cause of insulin resistance in humans, and, in many individuals, the first step in the development of type 2 diabetes and metabolic syndrome. The adverse metabolic effects of increasing fat mass depend heavily on its anatomical distribution, with visceral white adipose tissue (WAT) driving the development of insulin resistance and associated metabolic 20 diseases (1). In contrast increased subcutaneous WAT is not associated with insulin resistance and, in some circumstances, has even been shown to have protective effects (2, 1).

Expansion of adipose tissue is achieved by increased lipid storage in existing adipocytes and *de novo* differentiation of preadipocytes. Various autocrine, paracrine and endocrine factors control adipocyte differentiation (3). Among them insulin is important in regulation of 25 differentiation and lipid accumulation *in vitro* and *in vivo* (4). White adipose tissue is also an important endocrine organ, secreting various cytokines and hormones (adipokines) regulating whole body metabolism and insulin sensitivity (5, 6, 7).

It was previously identified that a set of developmentally -regulated genes that are differentially expressed in subcutaneous and visceral adipose tissue of mice and men (8). Among 30 these, the patterning gene glypican-4 (Gpc4) is not only differentially expressed in these depots, but its expression in human WAT is also highly correlated with body mass index (BMI) and adipose distribution as measured by waist-to-hip ratio (WHR). Gpc4 belongs to a six member family of glycosylphosphatidylinositol (GPI) anchored heparan sulfate proteoglycans. Lacking transmembrane and intracellular domains, glypicans function as co-receptors for a variety of 35 growth factors including Wnt, BMPs, FGF and Hedgehog (9, 10, 11). Little is known about the signaling functions of Gpc4. Mammalian Gpc4 has been reported to bind to FGF2 via its heparan sulfate chains in neuronal cells and to function as a low affinity receptor for endostatin (12, 13). The role of Gpc4 in adipocytes and its relationship to metabolic regulation remains unknown.

SUMMARY

Embodiments of this invention are based on our novel and non-obvious showings that Gpc4 is important for adipocyte differentiation by interacting with and regulating insulin receptor activation and its downstream signaling. This interaction is preserved in a soluble non-membrane anchored mutant of Gpc4. Furthermore, provided herein is evidence that Gpc4 is released from adipose tissue, and that serum Gpc4 is a marker for BMI and insulin sensitivity in mice and human. Thus, Gpc4 can serve as a novel adipokine being released from adipose tissue with the ability to enhance insulin sensitivity.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows Gpc4 is differentially regulated in subcutaneous and visceral WAT upon weight gain. *A*: Gpc4 expression in subcutaneous (SCW) and visceral (Vise.) fat of 77 female and 83 male nondiabetic subjects, ranging from lean to obese, grouped by BMI. Vise. BMI 25-30 and vise. BMI >30 indicates subjects with a CT or MRI ratio between subcutaneous and visceral fat areas >0.4 in the given BMI range. *B*: Western blot for Gpc4 from 6-week-old C57BL/6 male mice. Actin is used as loading control. C: qPCR for Gpc4 from the indicated fat depots of C57BL/6 mice fed an HFD for 8 weeks, *db/db* and control mice. Control mice are C57BL/6 chow diet-fed mice and *db/+* mice combined (HFD, $n = 4$; *db/db,* $n = 6$; controls, $n = 4\text{-}6$). BAT, brown adipose tissue; PGF, perigonadal fat; SCF, subcutaneous flank fat. $*P < 0.05$; $**P < 0.01$; $***p < 0.001$.

Figure 2 shows Gpc4 is essential for adipocyte differentiation. *A*: qPCR for Gpc4 from shGpc4 and control 3T3-L1 cells ($n = 9$). *B:* Western blot for Gpc4 and actin as loading control, from control and shGpc4 3T3-L1 preadipocytes. C: Oil Red O staining of shScr and shGpc4 cells at day 8 of differentiation with or without troglitazone (TZD). *D:* qPCR for key transcription factors of adipocyte differentiation during 8 days of differentiation ($n = 9$). *E:* Western blots from nuclear extracts of shScr and shGpc4 cells 24 h after induction of differentiation. *F:* Quantification of phospho-C/EBPβ on Thrl88 normalized to total C/EBPβ ($n = 3$), 24 h after induction. *G*: Western blots from oligonucleotide pull downs with a wild-type C/EBP binding motif (wt) or a mutant that is not bound by C/EBPβ as control (mut) 24 h after induction of differentiation. $**p < 0.01$; $***P < 0.001$; $****P < 0.0001$.

Figure 3 shows Gpc4 regulates insulin receptor activation and downstream signaling. *A*: Western blots from insulin- and IGF1R β-subunit immunoprecipitations of confluent shScr and shGpc4 preadipocytes, blotted for insulin/IGF 1R β and pTyrosine before and after 5 min of 10 nmol/L insulin stimulation. *B:* Quantification of tyrosine phosphorylated insulin receptor in 3T3-

LI preadipocytes, normalized to total insulin receptor levels (n = 6). C: Western blots of confluent shScr and shGpc4 preadipocytes from total cell lysates before and after 5-min stimulation with 10 nmol/L insulin. *D:* Quantification of ERK and AktS473 phosphorylation at 0, 5, 10, 20, 40, and 60 min after insulin stimulation. pERK and pAktS473 were normalized to total ERK and Akt levels (n 5 = 8). *E:* Area under the curve of AktS473 phosphorylation shown in *D*. *F:* Coimmunoprecipitation of Gpc4 with insulin and IGF1R β-subunit in 3T3-L1 cells. For all stimulation experiments, confluent undifferentiated preadipocytes were serum-starved for 3 h and stimulated with 10 nmol/L insulin. $**P < 0.01$; $***P < 0.001$.

Figure 4 shows overexpression of Gpc4 enhances adipocyte differentiation and insulin 10 signaling. *A*: Western blot for Gpc4 of 3T3-L1 stably infected with control lentivirus, native Gpc4, shGpc4, or AGpc4. In the AGpc4 mutant, the GPI attachment motif 529SAG53 1 was replaced with a 6xHis-tag. Actin was used as loading control. *B:* Western blot for Gpc4 from serum-free Opti-MEM conditioned for 24 h by the indicated cell lines. C: Oil Red O staining and brightfield images from control, Gpc4, and AGpc4 expressing cells taken at day 8 of differentiation. *D:* qPCR for 15 Glut4 and perilipin during an 8-day time course of differentiation of control, Gpc4, and AGpc4 overexpressing cells. *indicates significantly higher expression in AGpc4 versus control cells (n = 5). *E:* Ni-NTA pull downs of His-tagged AGpc4 from total cell lysates during normal growth conditions or after 5 min of 10 nmol/L insulin stimulation. *F:* Quantification of ERK and AktS473 phosphorylation at 0, 5, 10, 20, 40, and 60 min after 10 nmol/L insulin stimulation of confluent 20 3T3-L1 preadipocytes. pERK and pAktS473 were normalized to total ERK and Akt levels (n = 3). *G:* Western blot for Gpc4 of purified AGpc4 and control eluate. *H:* Insulin stimulation in presence or absence of purified recombinant AGpc4. Cells were pretreated with AGpc4 or control eluate during the 1-h serum starvation before 10 nmol/L insulin stimulation. All samples were run on one SDS gel; time points were separated for better visualization. $*P < 0.05$; $**P < 0.01$.

25 Figure 5 shows Gpc4 is released from adipocytes and correlates with markers of body fat and insulin resistance. *A*: Western blot for Gpc4 from conditioned serum-free Opti-M EM I of cultured isolated subcutaneous, perigonadal, and brown adipocytes and the corresponding SVF. Ponceau-S staining shows equal loading of proteins. Cells were isolated by collagenase digest and medium was conditioned for 12 h. *B*: Western blot of serum Gpc4. Glycoproteins from serum of 30 4-month-old C57BL/6 male and female mice were purified using anion exchange chromatography. Western blots from concentrated eluates were probed for Gpc4. C: Gpc4 ELISA from serum of C57BL/6 mice fed an HFD for 8 weeks, *ob/ob* and control mice. Control mice are C57BL/6 chow diet-fed mice and *ob/+* mice combined (n =6 per genotype). D: Gpc4 ELISA from serum of nondiabetic females (n =77) and males (n =83) grouped according to BM I and body fat

distribution. Visceral overweight and obesity is defined by a CT or MRI ratio >0.4 between subcutaneous and visceral fat areas. *E*: Comparison of BMI, WHR, and GIR during a euglycemic hyperinsulinemic clamp and HOMA-IR of the lowest and highest quartile of serum Gpc4 levels of females and males (*n* = 19 and 20 per quartile, respectively). *F*: Comparison of GIR from nonobese (BMI <30) and obese (BMI >30) subjects divided into groups with low serum Gpc4 levels (<5 ng/mL) and high serum Gpc4 levels (>9 ng/mL). *G*: Serum Gpc4 levels in 30 obese age-, sex-, and BMI-matched insulin-sensitive and insulin-resistant subjects. *$P < 0.05$; **$P < 0.01$; ***$p < 0.001$; ****$p < 0.0001$.

Figure 6 Amino acid sequences of human glypican-4 precursor [SEQ ID NO: 2] and mature proteins [SEQ ID NO: 3] as well as the nucleotide sequence of human glypican-4 precursor protein [SEQ ID NO: 1].

Figure 7 shows that Glypican-4 not only modulates insulin receptor affinity and is a serum marker for insulin resistance, as shown in the previous publication, but also regulates the secretion of insulin from pancreatic beta cells.

Figure 8 shows a Western blot for Gpc4 from purified _Gpc4 under reduced (red.) or not reduced (not. red.) conditions.

Figure 9 shows (A) Cell number of control and shGpc4 3T3-L1 at day 0 and day 2 of differentiation (n=3). (B) Quantification of Western blots for ERK and AktS473 phosphorylation during the first 49 hours of differentiation. Phospho- signals were normalized to total ERK and Akt, respectively. Induction medium was changed after 48 hours to growth medium containing 10% FBS and 170 nM insulin (n=3). (C) Western Blot for pIRS-lY612 and pY896 and total IRS-1. Differentiation was induced at time point 0. Induction medium was changed to growth medium after 48 hours.

Figure 10 shows (A) Insulin binding to confluent shScr and shGpc4 preadipocytes. 1251-insulin was competed with increasing concentrations of unlabeled insulin. Values were background subtracted and normalized to protein concentration. (n=6). (B) Western Blot for pAktS473, pErk and the respective unphosphorylated proteins of shScr and shGpc4 cells stimulated with the indicated concentrations of insulin for 20 minutes. (C) Western Blot for pAktS473, pErk and the respective unphosphorylated proteins of shScr and shGpc4 cells stimulated with 10% FBS after 3 hours serum withdrawal.

Figure 11 shows (A) Realtime PCR for Ppary, C/EBPa and C/EBPβ during an eight day time course of differentiation of control Gpc4 and AGpc4 overexpressing cells. * indicates significantly higher expression in AGpc4 and Gpc4 vs. control cells (n=5). (B) Quantification of phospho-C/EBPβ hrl 88 normalized to total C/EBPβ of control Gpc4 and AGpc4 overexpressing

cells 24h after induction (n=3). 14C-Deoxy-glucose uptake was measured in serum starved 3T3-L1 control or AGpc4 overexpressing adipocytes exposed for 45 minutes to 0 or IOOηM insulin (n=3).

Figure 12 shows qPCR for Gpc4 from freshly isolated perigonadal adipocytes and the corresponding SVF. Gpc4 expression was normalized to TBP (n=3).

Figure 13 shows (A) Murine Gpc4 protein sequence. Peptides identified by mass spectrometry are highlighted in red. (B) Correlation between serum Gpc4 and glucose and insulin levels in control, HFD fed (8 weeks) and ob/ob mice. (C) Comparison of clinical parameters from the lowest and highest quartile of serum Gpc4 levels of 160 patients shown in Figure 5D (n=40 per quartile).

Figure 14 shows (A) Correlation of serum Gpc4 with BMI and GIR in non-diabetic females (n=77) and males (n=83). (B) Comparison of HOMA-IR and BMI from non-obese (BMK30) and obese (BMI>30) subjects divided into groups with low serum Gpc4 levels (<5 ng/ml) and high serum Gpc4 levels (> 9 ng/ml).

Figure 15 shows Real Time PCR for the GPI lipases Gpldl and Notum in liver, subcutaneous (SCF) and perigonadal fat (PGF) of control (ob/+) and ob/ob mice. Expression values were normalized to TBP (n=6).

DETAILED DESCRIPTION

Provided herein are methods for increasing insulin sensitivity in a subject. A method may comprise administering to a subject in need of increased insulin sensitivity a therapeutically effective amount of a glypican-4 agent. Also provided herein are methods for determining whether a subject is or is likely to become insulin resistant. A method may comprise determining the level of glypican-4 in a subject, wherein an elevated level of glypican-4 indicates that a subject is or is likely to become insulin resistant.

The invention is based at least on the discovery that circulating glypican-4 levels correlate with body mass index and insulin sensitivity in humans, and that glypican-4 interacts with the insulin receptor and enhances insulin receptor signaling and enhances adipocyte differentiation.

Glypican-4 is also known as RP6-198C21.1, K-glypican and has Gene ID: ID:2239. The human glypican-4 precursor protein consists of 556 amino acids, of which amino acids 1-22 correspond to the signal peptide. The amino acid sequence of the precursor protein is provided as GenBank Accession No. NP_001439 and is set forth herein as SEQ ID NO: 2 (Figure 6). The

amino acid sequence of the mature protein, corresponding to amino acids 23-556 of SEQ ID NO: 2 is set forth as SEQ ID NO: 3 (Figure 6). The nucleotide sequence encoding the human glypican-4 precursor protein is provided as GenBank Accession No. 1.NM_001448.2 and is set forth herein as SEQ ID NO: 1.

In certain embodiments, a method comprises administering to a subject a glypican-4 agent. An "agent" can be any type of molecule, including a peptide, polypeptide, protein, nucleic acid (e.g., RNA or DNA) or other type of molecule that mimics glypican-4 or induces a biological response that is induced by a wild type or naturally occurring glypican-4. In preferred embodiments, a glypican-4 agent is a protein that binds to (or interacts with) the insulin receptor when insulin is not bound to the receptor. In certain embodiments, a glypican-4 agent is a protein comprising all or a portion of SEQ ID NO: 2 or 3, or a protein comprising an amino acid sequence that is at least 70%, 80%, 90%, 95%, 97%, 98%, or 99% identical to SEQ ID NO: 2 or 3. Amino acid differences may be amino acid substitutions, e.g., a conservative amino acid substitution, amino acid deletions or additions. In certain embodiments, a glypican-4 agent is a protein comprising an amino acid sequence that differs from an amino acid sequence of the naturally occurring human glypican-4, e.g., having SEQ ID NO: 2 or 3, and comprising at most 100, 80, 50, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 amino acid differences, e.g., amino acid substitutions, deletions or additions.

In certain embodiments, a glypican-4 agent comprises, consists or consists essentially of, a fragment of glypican-4 and comprising, e.g., up to 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450 or 500 consecutive amino acids of a full length glypican-4 protein, e.g., a human glypican-4 protein having SEQ ID NO: 2 or 3. In certain embodiments, a glypican-4 agent is a protein that is at least 70%, 80%, 90%, 95%, 97%, 98%, or 99% identical to a fragment of a wild type or naturally occurring glypican-4, e.g., a human glypican-4 consisting of SEQ ID NO: 2 or 3.

A glypican-4 agent may also be a fusion protein comprising, e.g., a glypipcan-4 protein or fragment or analog thereof, that is covalently linked to an unrelated protein or peptide to, e.g., stabilize the glypican-4 protein or fragment or analog thereof, facilitate transport to the proper target tissue (e.g., adipose tissue) or increase its solubility. In one embodiment, a glypican-4 protein or portion or analog thereof (e.g., a protein that is similar to a naturally occurring glypican-4 protein, e.g., a protein having SEQ ID NO: 2 or 3) is fused to an immunoglobulin constant region, e.g., an IgG constant region, which may comprise the hinge, CH2 and/or CH3 domains.

In certain embodiments, a glypican-4 agent comprises a GPI-anchor, such as the naturally-

occurring GPI anchor that is present on a naturally occurring glypican-4. A glypican-4 agent may also be an agent that does not comprise a GPI-anchor, such as a protein in which it was specifically deleted or its site of attachment was mutated so as to prevent its attachment to a GPI- anchor. A glypican-4 agent that is deprived of a GPI-anchor is a soluble glypican-4 protein or analog thereof. As shown herein, soluble glypican-4 agents also bind to the insulin receptor and increase insulin sensitivity.

In certain embodiments, a nucleic acid encoding a glypican-4 agent is administered to a subject. A nucleic acid may comprise the coding sequence of a glypican-4 protein or analog thereof operably linked to a promoter and optionally an enhancer and any other elements necessary for expressing the glypican-4 protein or analog from the nucleic acid. A nucleic acid may be a vector, such as an expression vector, e.g., viral vector. The nucleic acid may express the glypican-4 protein or analog in a tissue specific manner, e.g., specifically in adipose tissue, such as white adipose tissue.

Methods of treatment

Provided herein are methods for treating a subject comprising administering to the subject a glypican-4 agent to increase the subject's sensitivity to insulin. A method may comprise administering to a subject in need thereof a therapeutically effective amount of a glypican-4 agent, e.g., to increase insulin sensitivity of the subject.

The term "effective amount" as used herein means an amount effective, at dosages and for periods of time necessary to achieve the desired result, for example, to treat the specific disorder.

The term "treating" refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilization of the state of disease, prevention of spread or development of the disease or condition (e.g., insulin resistance), delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total). "Treating" can also mean prolonging survival of a patient beyond that expected in the absence of treatment. "Treating" can also mean inhibiting the progression of disease, slowing the progression of disease temporarily, although more preferably, it involves halting the progression of the disease permanently. A method may increase insulin sensitivity by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%>, 90%>, 100%> (2 fold), 3 fold, 5 fold or more. A method may reduce insulin resistance by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% (2 fold), 3 fold, 5 fold or more.

Insulin sensitivity or resistance may be measured by methods known in the art, e.g., as further described herein.

A subject who may be treated by administration of a glypican-**4** agent may be a subject in need of increased insulin sensitivity, e.g., an insulin resistant subject or a subject who is likely to become insulin resistant. For example, a subject in need of increased insulin sensitivity may be a subject who is overweight or obese, and has, e.g., a BMI $\geq$ 25 or 30. A subject in need of a glypican-**4** agent may also be a subject having the metabolic syndrome, type **1** diabetes, type 2 diabetes or a subject having hyperlipidemia or hyperglycemia. A subject may be a mammal, such as a human.

A method may comprise first identifying a subject as being in need of glypican-**4,** such as a subject who is in need of an agent for increasing insulin sensitivity, and if a subject has been identified as such, then administering to the subject a glypican-**4** agent. A method may comprise determining whether a subject (i) is insulin resistant or likely to become insulin resistant; (ii) has metabolic syndrome (syndrome X); (iii) has type 2 diabetes; (iv) had type **1** diabetes; (v) is obese; (vi) is overweight; (vii) has hyperglycemia; (viii) has hyperlipidemia; or (ix) has any pre-insulin resistance characteristics; and if the subject has any one or more of these conditions, then administering to the subject a glypican-**4** agent.

A method may also first comprise determining whether the subject would be responsive to a glypican-**4** therapy, e.g., as further described below, and if the subject is determined to be a likely responder to a glypican-**4** agent therapy, then administering to the subject a glypican-**4** agent.

Administration of a glypican-**4** agent to a subject may be systemic or local. Local administration may include administration into a tissue having cells that have insulin receptors, e.g., adipose tissue, such as white adipose tissue.

Also provided herein are methods for stimulating the differentiation of a preadipocyte. A method may comprise contacting a pre-adipocyte with a glypican-**4** agent to stimulate its differentiation. A pre-adipocyte may be an isolated cell or in a cell population. A pre-adipocyte may be obtained from a subject or be a cell line. In one embodiment, a pre-adipocyte (or a population of pre-adipocytes) is obtained from a subject and contacted ex vivo with a glypican-**4** agent to stimulate their differentiation into adipocytes.

Therapeutic administration and pharmaceutical compositions

A therapeutic (e.g., a glypican-4 agent) may be administered to a patient using standard techniques known in the art. The therapeutic may be administered systemically, or may be administered directly at the site at which a target cell is located, e.g., white adipose tissue. Delivery to the site includes topical administration, injection to the site, or surgical implantation, for example in white adipose tissue. A treatment may comprise one or more doses, which may be daily, weekly, monthly or according to another regimen, as determined by a physician.

The concentration and amount of the therapeutic to be administered will vary, depending on the disorder to be treated, the type of therapeutic that is administered, the mode of administration, and the age and health of the patient. However, a person of skill in the art will be able to determine the proper amount.

To aid in administration, the therapeutic may be formulated as an ingredient in a pharmaceutical composition. Therefore, in a further embodiment, there is provided a pharmaceutical composition comprising a therapeutic, and a pharmaceutically acceptable diluent. Therefore, also provided herein are pharmaceutical compositions for use in treating a disorder, such insulin resistance. The compositions may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives and various compatible carriers. For all forms of delivery, the therapeutic may be formulated in a physiological salt solution. Therapeutics may be incorporated in a liposome or other biomaterial useful for protecting and/or preserving the therapeutic until it is delivered to the target cell. A liposome may also help target a therapeutic to a desired location, e.g., white adipose tissue or skeletal tissue.

A pharmaceutical composition may additionally contain other therapeutic agents useful for treating a disorder, such as other agents for treating obesity, insulin resistance, glucose intolerance, hyperlipidemia, Syndrome X or Type II diabetes. For example, a composition may comprise a glypican-4 agent and a second therapeutic for treating obesity, insulin resistance, glucose intolerance, hyperlipidemia, Syndrome X or Type II diabetes, e.g., a PPAR-γ agonist, such as a thiazolidinedione. Exemplary thiaxolidinediones include Rosiglitazone (AVANDIA), Pioglitazone (Actos), Troglitazone (Rezulin), Rivoglitazone (MCC-555) and Ciglitazone. Combinations may be present in a single pharmaceutical compositions, or in different pharmaceutical compositions, which are administered simultaneously or sequentially to a subject.

For example, a subject receiving a glypican-4 agent may also receive one or more of the following drugs for treating obesity:

- Catecholamines and their derivatives, such as phentermine (e.g., Adipex-P) and other amphetamine based drugs; metamphetamine-based drugs (e.g., Desoxyn and Desoxyn Gradumet) and benzphetamine based drugs (e.g., Didrex); phendimetrazine (e.g., Adipost;

Appecon; Bontril PDM; Bontril Slow Release; Melfiat); phentermine (lonamin; Obenix; Obezine; Oby-Cap; Phendiet; Plegine; Prelu-2; Prelu-2 TR; Pro-Fast SA; Statobex; T-Diet; Teramine; Zantryl);

5 • anti-depressants and mood stabilizers, such as bupropion; topiramate; diethylpropion (e.g., Tenuate; Tenuate Dospan; Tepanil);

• drugs blocking the cannabinoid receptors;

• drugs that increase of the body's metabolism;

10

• drugs that interference with the body's ability to absorb specific nutrients in food (such as Orlistat (Xenical; AllT); glucomannan and guar gum;

• Anorectics (such as dexedrine and digoxin); and

15 · Others: ZGN-433 ; GT 389-255 (being developed by Peptimmune).

A subject receiving a glypican-4 inhibitor may also receive one or more of the following drugs for treating Type II diabetes:

20 • Insulin sensitizers, such as Biguanides, e.g., Metformin (Glucophage); Thiazolidinediones (TZDs), also known as "glitazones," that bind to PPARy and include rosiglitazone (Avandia; Avandaryl; Avandamet), pioglitazone (Actos), troglitazone (Rezulin; withdrawn) and Darglitazone;

25 • Secretagogues, such as Sulfonylureas, e.g., tolbutamide (Orinase; Tol-Tab); acetohexamide (Dymelor); tolazamide (Tolinase); chlorpropamide (Diabinese); glipizide (Glucotrol; Glucotrol XL; GlipiZIDE XLGlipiZIDE XL; Metaglip); glyburide (Diabeta, Micronase, Glynase); glimepiride (Amaryl; Duetact); gliclazide (Diamicron); DiaBeta; Diabinese; Glycron; Glynase; and Glynase PresTab;

• Nonsulfonylurea secretagogues, such as Meglitinides, e.g., repaglinide (Prandin); nateglinide (Starlix); Fortamet; Glumetza; PrandiMet; and Riomet

30 · Alpha-glucosidase inhibitors, e.g., miglitol (Glyset); and acarbose (Precose/Glucobay; Precose);

• Peptide analogs, such as Incretin mimetics, e.g., glucagon-like peptide-1 (GLP-1); gastric inhibitory peptide (glucose-dependent insulinotropic peptide, GIP), such as Exenatide (also Exendin-4, marketed as Byetta); Liraglutide (Victoza); and Taspoglutide;

35 · Gastric inhibitory peptide analogs;

• Injectable peptide analogs, such as Dipeptidyl peptidase-4 (DPP-4) inhibitors, e.g., vildagliptin (Galvus); sitagliptin (Januvia; Janumet); saxagliptin (Onglyza; Kombiglyze XR); linagliptin (Tradjenta); and Alogliptin;

- Amylin analogues, such as pramlintide (Symlin; Symlin Pen; SymlinPen 120; SymlinPen 60); and

5

- Others: APD597 (Arena Pharmaceuticals); salsalate; and salsalte analogues and derivatives; Welchol; Cr-GTF; CRM; Cycloset; ActoPlus Met; ActoPlus Met XR; Glucovance.

A subject receiving a glypican-4 may also receive one or more of the following drugs for insulin resistance: glucosamine, rifampicin, isoniazid, olanzapine, risperidone, progestogens, corticosteroids, glucocorticoids, methadone, many antiretrovirals, metformins thiazolidinedione, and Exenatide (Byetta).

10

A preferred embodiment of the present invention is the administration of a pharmaceutically acceptable formulation of a glypican-4 agent. A "pharmaceutically acceptable formulation" is one that is suitable for administering a glypican-4 in a manner that gives the desired results and does not also produce adverse side effects sufficient to convince a physician that the potential harm to a patient is greater than the potential benefit to that patient.

15

A pharmaceutical composition may be prepared by known methods for the preparation of pharmaceutically acceptable compositions suitable for administration to patients, such that an effective quantity of the therapeutic and any additional active substance or substances, is combined in a mixture

20

with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the pharmaceutical compositions include, albeit not exclusively, solutions of the therapeutic in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffer solutions with a suitable pH and iso-osmotic with physiological fluids.

25

30

The proportion and identity of a pharmaceutically acceptable diluent used with a therapeutic is determined by the chosen route of administration, compatibility with live cells, and standard pharmaceutical practice. Generally, a pharmaceutical composition will be formulated with components that will not kill or significantly impair the biological properties of the therapeutic.

35

A pharmaceutical composition may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. For example, a composition may be administered topically, surgically or by injection to the desired site. In certain embodiments, a therapeutic is administered topically or by injection (subcutaneously, intravenously, intramuscularly, etc.) directly at the desired site where the target

cells, e.g., white adipose cells, are located in the patient.

Administration of a glypican-4 may also be combined with a weight reducing diet and/or exercise.

Diagnostic and prognostic methods

Also provided herein are methods for determining the level of insulin sensitivity or resistance of a subject or whether a subject is or is likely to become insulin resistant. A method may comprise providing a sample from a subject and determining the level of glypican-4 in the sample, wherein a level of glypican-4 that is higher than the level of glypican-4 in a subject who is not insulin resistant indicates that the subject is or is likely to become insulin resistant, whereas a level of glypican-4 that is similar to or lower than that in a subject who is not insulin resistant indicates that a subject is not insulin resistant and is not likely to become insulin resistant. A method may further first comprise obtaining a sample from a subject.

A method may comprise obtaining a sample from a subject, e.g., a sample of tissue or biological fluid. A sample of tissue may be a sample of a tissue comprising cells having an insulin receptor. A sample of tissue may be, e.g., adipose tissue, such as white adipose tissue, or muscle tissue. A sample of biological fluid may be a sample of blood, serum, urine or tears.

In one embodiment, a method may comprise determining the level of glypican-4 in the serum of a subject (e.g., in a sample of serum from the subject), wherein a level of glypican-4 that is $\geq$ 7 ng/ml, 9 ng/ml or 10 ng/ml (preferably $\geq$ 9 ng/ml) indicates that the subject is insulin resistant or likely to become insulin resistant. In one embodiment, the subject is not obese or overweight. As described herein, non obese subjects (BMI < 30) with high serum glypican-4 (> 9 ng/ml) levels showed the same degree of insulin resistance as measured by euglycemic clamp, fasting plasma insulin and HOMA-IR as obese subjects, independent of serum glypican-4 levels. Thus, in one embodiment, a method for determining whether a non-obese subject (BMI < 30) is insulin resistant or likely to become insulin resistant, comprises:

(i) providing a sample of serum from the subject; and

(ii) determining the level of glypican-4 in the serum of the subject, wherein a level of glypican-4 in the serum sample that is higher than a control value (e.g., a statistically significant level of glypican-4 in subjects who are not insulin resistant), indicates that the subject is or is likely to become insulin resistant; whereas a level of glypican-4 in the serum sample that is similar to or lower than the control value indicates that the subject is not or is not likely to become insulin resistant. A control value may be, e.g., 4 ng/ml, 5 ng/ml, or 6 ng/ml.

Also provided herein are methods for determining whether a subject is responding to a treatment for insulin resistance or for increasing insulin sensitivity. A method may comprise providing a sample of a subject that is being treated for insulin resistance and determining the level of glypican-4 in the sample; wherein a higher level of glypican-4 in the sample relative to that at an earlier time during the treatment or prior to the treatment indicates that the subject is not responding to the treatment, whereas a lower level of glypican-4 in the sample relative to that at an earlier time during the treatment or prior to the treatment indicates that the subject is responding to the treatment. A sample may be a serum sample.

Further provided are methods for determining whether a subject is likely to respond to a treatment for insulin resistance or for increasing insulin sensitivity. A method may comprise providing a sample of a subject that has received a dose (e.g., a single dose) of a drug for treating insulin resistance or increasing insulin sensitivity, and determining the level of glypican-4 in the sample; wherein a higher level of glypican-4 in the sample relative to that prior to the administration of the drug indicates that the subject is not likely to respond to the drug, whereas a lower level of glypican-4 in the sample relative to that prior to the administration of the drug indicates that the subject is likely to respond to the drug. A sample may be a serum sample. A drug for insulin resistance may be a glypican-4 agent. If the drug is a glypican-4 agent, then the method specifically measures the naturally-occurring glypican-4 for determining the likelihood of response of the subject to a glypican-4 treatment. A drug may also be PPAR-γ agonist, such as a thiazolidinedione. Exemplary thiaxolidinediones include Rosiglitazone (AVANDIA), Pioglitazone (Actos), Troglitazone (Rezulin), Rivoglitazone (MCC-555), Ciglitazone. The assays described herein may also be used to determine the response of a subject to any of the following insulin resistance therapeutics:

glucosamine, rifampicin, isoniazid, olanzapine, risperidone, progestogens, corticosteroids, glucocorticoids, methadone, many antiretrovirals, metformin,a thiazolidinedione, and Exenatide (Byetta).

If a subject is determined as a likely responder to a therapeutic (drug) for increasing insulin sensitivity or reducing or preventing insulin resistance, then a method may comprise administering to the subject the therapeutic for increasing insulin sensitivity or reducing or preventing insulin resistance.

Instead of determining the level of glypican-4, a method may comprise determining the level of signal transduction that is induced by the action of glypican-4 on its target, e.g., the insulin receptor. For example, a method may comprise measuring the level of transactivation of C/EBPa and/or PPARy.

Also provided herein are compositions for diagnostic/prognostic and biomarker applications. A composition may comprise a reagent for determining the level of glypican-4 in a sample. A reagent may be any molecule or complex of molecules that can bind to glypican-4, such as an antibody or antigen binding fragment thereof or a portion of an insulin receptor to which glypican-4 binds. A composition may also comprise one or more reagents necessary for detecting and/or measuring activation of the signal transduction pathway that is induced by glypican-4, e.g., in adipose cells.

Also provided are kits for diagnostic/prognostic and biomarker applications. A kit may comprise a reagent for detecting glypican-4 and one or more other compositions or elements that may be necessary for measuring glypican-4 levels in a sample. Kits may also comprise reagents necessary for detecting and/or measuring activation of the signal transduction pathway that is induced by glypican-4, e.g., in adipose cells.

Assays for identifying therapeutics for treating insulin resistance

Further provided herein are assays that may be used to identify agents for increasing insulin sensitivity or for treating insulin resistance. An assay may comprise identifying an agent that binds to the insulin receptor or IGF1R in a similar manner as glypican-4 binds to the insulin receptor or IGF1R. A method may comprise contacting an insulin receptor or IGF1R or fragment or analog thereof that binds to glypican-4 with a test compound and determining whether the test compound binds to the insulin receptor or IGF1R or fragment or analog thereof, wherein a test compound that binds to the insulin receptor or IG1R or fragment or analog thereof indicates that the test compound is a compound that may be used for increasing insulin sensitivity. The assay may be following by additional assays that are used for determining the effect of a drug on insulin resistance.

Also provided are isolated complexes comprising, e.g., a glypican-4 protein or fragment or analog thereof and an insulin receptor or IGF1R fragment or analog thereof. Compositions comprising these isolated complexes are also encompassed herein. Compositions may further comprise additional ingredients, e.g., a test compound.

In certain embodiments, a method may comprise contacting an insulin receptor or portion or analog thereof with glypican-4 or fragment or analog thereof that binds to the insulin receptor in the presence of a test compound and determining whether the test compound affects the binding of the insulin receptor or fragment or analog thereof with glypican-4 or fragment or analog thereof. A compound that increases the binding of the insulin receptor and glypican-4 is a compound that may

increase insulin sensitivity.

In some embodiments, the test compounds are initially members of a library, e.g., an inorganic or organic chemical library, peptide library, oligonucleotide library, or mixed-molecule library. In some embodiments, the methods include screening small molecules, e.g., natural products or members of a combinatorial chemistry library.

A given library can comprise a set of structurally related or unrelated test compounds. Preferably, a set of diverse molecules should be used to cover a variety of functions such as charge, aromaticity, hydrogen bonding, flexibility, size, length of side chain, hydrophobicity, and rigidity. Combinatorial techniques suitable for creating libraries are known in the art, e.g., methods for synthesizing libraries of small molecules, e.g., as exemplified by Obrecht and Villalgordo, Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries, Pergamon-Elsevier Science Limited (1998). Such methods include the "split and pool" or "parallel" synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, Curr. Opin. Chem. Bio. 1:60-6 (1997)). In addition, a number of libraries, including small molecule libraries, are commercially available.

In some embodiments, the test compounds are peptide or peptidomimetic molecules, e.g., peptide analogs including peptides comprising non-naturally occurring amino acids or having non-peptide linkages; peptidomimetics (e.g., peptoid oligomers, e.g., peptoid amide or ester analogues, .beta.-peptides, D-peptides, L-peptides, oligourea or oligocarbamate); small peptides (e.g., pentapeptides, hexapeptides, heptapeptides, octapeptides, nonapeptides, decapeptides, or larger, e.g., 20-mers or more); cyclic peptides; other non-natural or unnatural peptide-like structures; and inorganic molecules (e.g., heterocyclic ring molecules). In some embodiments, the test compounds are nucleic acids, e.g., DNA or RNA oligonucleotides.

In some embodiments, test compounds and libraries thereof can be obtained by systematically altering the structure of a first test compound. Taking a small molecule as an example, e.g., a first small molecule is selected that is, e.g., structurally similar to glypican-4. For example, in one embodiment, a general library of small molecules is screened, e.g., using the methods described herein, to select a fist test small molecule. Using methods known in the art, the structure of that small molecule is identified if necessary and correlated to a resulting biological activity, e.g., by a structure-activity relationship study. As one of skill in the art will appreciate, there are a variety of standard methods for creating such a structure-activity relationship. Thus, in some instances, the work may be largely empirical, and in others, the three-dimensional structure of an endogenous polypeptide or portion thereof can be used as a starting point for the rational design of a small molecule compound or compounds.

In some embodiments, test compounds identified as "hits" in a first screen are selected and optimized by being systematically altered, e.g., using rational design, to optimize binding affinity, avidity, specificity, or other parameter. Such potentially optimized structures can also be screened using the methods described herein. Thus, in one embodiment, the invention includes screening a first library of test compounds using a method described herein, identifying one or more hits in that library, subjecting those hits to systematic structural alteration to create one or more second generation compounds structurally related to the hit, and screening the second generation compound. Additional rounds of optimization can be used to identify a test compound with a desirable therapeutic profile.

Test compounds identified as hits can be considered candidate therapeutic compounds, useful in the methods of treating and preventing disorders described herein. Thus, the invention also includes compounds identified as "hits" by a method described herein, and methods for their administration and use in the treatment, prevention, or delay of development or progression of a disease described herein. The following examples should not be construed as limiting the scope of this disclosure.

EXEMPLIFICATION

Materials and methods

Human subjects

Paired samples of visceral and subcutaneous adipose tissue were obtained from 160 subjects as previously described and as known by one of ordinary skill in the art (8). All subjects gave written informed consent before taking part in the study.

Mice

All protocols were approved by the Institutional Animal Care and Use Committee of the Joslin Diabetes Center and in accordance with NIH guidelines. Mice (Jackson Lab; Bar Harbor, ME) were maintained on a 12h-light/dark cycle and fed a chow diet (9F5020; PharmaServ; Framingham, MA) or high fat diet (OpenSource Diet D 12492, Research Diet; New Brunswick, NJ).

Constructs

Gpc4 cDNA clones were obtained from Open Biosystems (Waltham, MA). An HA-tag was inserted after the signal peptide for native Gpc4 and the cDNA was cloned into the pCDH-

puro lentiviral vector (Systems Biosciences; Mountain View, CA). Gpc4A529SAG531::HHHHHH (AGpc4) was created by site directed mutagenesis (Stratagene) using the primers fwd:CGAGAAAGCTGACCACCATCACCATCACCATGGTGCCCATGCAG [SEQ ID NO: 4] rev:CTGCATGGGCACCATGGTGATGGTGATGGTGGTCAGCTTTCTCG [SEQ ID NO: 5]. A 6xHis tag was inserted at the N-terminus after the signal peptide and cloned into the pCDH-puro vector. All constructs were sequence verified. shRNA lentiviral vectors (pLKO.l) were obtained from Open Biosystems. shGpc4 shRNA was targeted against the sequence GCCACTGGTTTAAGCAATGTT [SEQ ID NO: 6]. A scrambled shRNA (shScr) targeting the sequence AGGTTAAGTCGCCCTCG [SEQ ID NO: 7] served as control.

Oligonucleotide pull-down assays

Pull downs were performed as previously described and as known by one of ordinary skill in the art (29).

Cell culture

3T3-L1 cells were cultured in DMEM 4.5g/l glucose, 10% FBS and 2.5 g/ml puromycin. Differentiation was induced with 170nM insulin, 500μM IBMX, 400ng/ml dexamethasone with or without IμM troglitazone (TZD). Oil Red O staining was performed as previously described and as known by one of ordinary skill in the art (33). Lentiviruses were produced in 293FT cells using the packaging plasmids psPAX2 and pMD2.G.

Quantitative real time PCR (qPCR)

cDNA synthesis and qPCR were performed as previously described and as known by one of ordinary skill in the art (1). Relative expression levels were calculated by the AACt method using TBP as reference. The primers used are described in (8,29).

Western Blots

Cells were lysed in 150mM NaCl, 50mM Tris-HCl (pH7.4), ImM EDTA, 1% Triton X-100 with protease and phosphatase inhibitors (Sigma; St. Louis, MO). The following antibodies were used: HRP-Actin (SantaCruz; Santa Cruz, CA), pTyrosine (4G10), pIRS-lY896 (Biosource; Grand Island, NY) pIRSY612 (Invitrogen; Grand Island, NY), IRS-1 (BD), pC/EBPpThrl88, C/EBPa, C/EBPβ, pAktS473, Akt, pERK, Erk, IRβ (all Cell Signaling; Danvers, MA). The Gpc4 antibody was raised against the peptide: EVRRLYVSKGFNKNDAPLYE (aa 32-52) [SEQ ID NO: 8] in rabbits and affinity purified against the peptide.

Immunoprecipitations

Protein lysates were incubated with mouse insulin receptor antibody (Cell-Signaling; Danvers, MA) overnight. Co-Immunoprecipitation was performed using magnetic protein-A micro beads and μColumns (Miltenyi; Cambridge, MA). For the quantification of insulin receptor phosphorylation, insulin receptor was precipitated using protein A/G agarose (Santa Cruz Biotechnology; Santa Cruz, CA).

ELISA

Serum Gpc4 was assessed by ELISA (USCNK Life Science; Houston, TX), using 50μl murine or human serum following to the manufacturer's recommendation.

AGpc4 purification

AGpc4 was purified from conditioned Opti-MEM of AGpc4 overexpressing 3T3-L1 cells. Medium from shScr cells was used as control. After 48 hours, 400ml medium was pooled and concentrated to 50ml, dialyzed against PBS/10% glycerol and incubated with 500μl Ni-NTA agarose (Qiagen; Hilden, Germany) overnight. AGpc4 was eluted in 300mM NaCl, 50mM NaH_2PO_4, 10mM imidazole, 0.05% Tween (pH8.0) containing 250mM imidazole. Eluates were dialyzed overnight to PBS/10% glycerol and concentrated with Centricon filters to 150μl.

Serum proteoglycan purification

Anion exchange chromatography was performed as described (31), dialyzed against PBS/10% glycerol, concentrated using Centricon filters (Millipore; Bellerica, MA) to 50μl and analyzed by SDS-PAGE.

Mass spectrometry

Serum proteoglycan preparations from 5 four month-old male C57BL/6 mice were reduced and denatured in buffer containing 2.5% β-mercaptoethanol and resolved on 4-12% gradient acrylamide gels (Invitrogen; Grand Island, NY). Gels were stained with Safestain (Invitrogen), and the gel fragment between 30-75kDa was submitted for mass spectrometric analysis to the Joslin Proteomics Core Facility.

Insulin binding assay

^{125}I insulin (MP Biomedicals; Santa Ana, CA) binding to adherent cells was measured as previously described and as known by one of ordinary skill in the art (32).

Statistical analysis

Statistical analysis was performed using GraphPad Prism (San Diego, CA) and presented as mean±SEM. Significance was tested with unpaired t-test, one-way or two-way ANOVA. A p-value <0.05 was considered significant. Multivariate regression analysis was performed using StatView (Cary, NC).

Results

Gpc4 expression in fat of humans correlates with body fat content and insulin sensitivity

It was previously shown that Gpc4 is differentially expressed between visceral and subcutaneous fat in rodents and humans, and that expression in adipose tissue of humans is strongly correlated with BMI and WHR (8). Further analysis revealed that Gpc4 expression in subcutaneous fat was markedly decreased in both males and females when comparing lean (BMK25) to overweight (BMI25-25) and obese (BMI>30) subjects (Figure 1A). In contrast, expression of Gpc4 in visceral fat was increased in overweight and obese males and females. When grouped by BMI, Gpc4 expression in visceral adipose tissue was highest in overweight subjects with high visceral fat, defined by a CT or MRI ratio between subcutaneous and visceral fat areas >0.4. Interestingly, in both females and males, this relationship was bell-shaped with the highest levels of Gpc4 expression in overweight individuals with a visceral fat distribution and lower levels in individuals with frank visceral obesity, who expressed Gpc4 at almost the same levels as lean individuals.

Multiple clinical parameters differed between these groups (Table 3). Therefore multivariate analysis was peformed of Gpc4 expression in visceral and subcutaneous fat versus 14 different clinical parameters that revealed a significant negative correlation of subcutaneous Gpc4 expression with WHR, and a negative correlation of Gpc4 expression in visceral fat with glucose infusion rate (GIR) during euglycemic hyperinsulinemic clamps (Table 1). These correlations were independent from the association of Gpc4 expression with body fat content and distribution, suggesting a link between Gpc4 expression and insulin sensitivity.

Gpc4 expression in fat of rodents at the niRNA and protein level

It was previously shown that in mice Gpc4 mRNA expression is two-fold higher in perigonadal than in subcutaneous fat (8). To better understand Gpc4 physiology in the rodent, a peptide antibody against murine Gpc4 was raised and used this to assess Gpc4 protein levels in

tissues and serum of mice. As expected, Western blots of extracts from 3T3-L1 preadipocytes run under non-reducing conditions for native Gpc4 revealed a broad smear from ~1 OOkDa to >170kDa, representing the 63kDa core protein with the attached heparan sulfate chains of varying lengths (Figure 8). As previously described and as known by one of ordinary skill in the art, the core protein of Gpc4 undergoes furin-mediated cleavage creating two disulfide-linked subunits of Gpc4 (11). Thus, when these same extracts were run under reducing conditions, the proteolytically cleaved N-terminal a-subunit of Gpc4 was detected as a sharp band at 37kDa, allowing more precise quantitation (Figure 8).

Using this assay, it was found that the difference in expression of Gpc4 between the murine fat depots was even more marked at the protein than at the mRNA level, and that perigonadal fat had ~5-fold higher Gpc4 levels than subcutaneous and brown adipose tissue (Figure IB). As in humans, Gpc4 expression in perigonadal fat of mice showed a bell-shaped relationship with level of obesity with upregulation of Gpc4 expression in mice with mild obesity due to high fat diet (HFD), and lower levels in the very obese db/db mice. In subcutaneous fat, Gpc4 expression was also increased in HFD fed mice and increased even further in db/db mice in this depot. This regulation by obesity state was specific to white adipose tissue with no change in Gpc4 in brown adipocyte tissue (BAT) in either the HFD or db/db mice (Figure 1C).

Role of Gpc4 in adipocyte differentiation and insulin signaling

To better understand the functional link between Gpc4 and adipogenesis 3T3-L1 preadipocytes were created with stable knockdown of Gpc4 using lentivirally-expressed shRNA (shGpc4). This resulted in a >95% depletion of Gpc4 mRNA (Figure 2A) and a reduction of Gpc4 protein below the limits of detection when compared to control cells infected with scrambled shRNA (shScr) (Figure 2B). The control 3T3-L1 cells differentiated efficiently into adipocytes within eight days after induction as visualized by Oil Red **O** (Figure 2C). In contrast, Gpc4 knockdown cells failed to accumulate lipids. Furthermore, while stimulation by thiazolidinediones enhanced the differentiation of control cells, this had no significant effect on shGpc4 cells (Figure **2C).**

Failure to accumulate lipids was due to a blockade in differentiation. qPCR revealed that Gpc4 knockdown cells induced early adipogenic markers C/EBPβ and C/EBPδ at levels comparable to control. By contrast, treatment of knockdown cells with induction cocktail did not induce the key downstream transcription factors for adipogenesis C/EBPa and PPARy, which were robustly increased in control cells (Figure 2D) (14). Western blots from nuclear extracts 24h after induction confirmed similar protein levels of C/EBPβ and C/EBPδ between control and

knockdown cells (Figure 2E), however, the important regulatory phosphorylation of C/EBPβ Thrl88 was reduced 54% in Gpc4 knockdown cells compared to controls (Figure 2E-F). Pull-downs from nuclear lysates from these cells with oligonucleotides containing a C/EBP binding site revealed similar binding of C/EBPβ from control and shGpc4 cells, however the bound C/EBP
5 from Gpc4 knockdown cells showed greatly reduced Thrl88 phosphorylation indicating diminished activation of this key transcription factor (Figure 2G). In addition to its role as activator of C/EBPa and PPARy transcription, C/EBPβ is essential for clonal expansion in 3T3-L1 preadipocytes (15), and consistent with the diminished phosphorylation/activation of C/EBPβ reduced mitotic clonal expansion in knockdown cells was also observed (Figure 9A).

10 Phosphorylation of C/EBPβ on Thrl88 is mediated by MAPK and PI3-Kinase signaling (16). Assessment of the phosphorylation/activation of ERK and Akt during the first 49h of differentiation revealed a tendency for lower AktS473 phosphorylation, but no alterations of ERK phosphorylation (Figure 9B). Phosphorylation of IRS-1 on Y612 and Y896, sites required for insulin-mediated Akt and ERK activation, showed reduced phosphorylation, suggesting an effect
15 of Gpc4 deletion on insulin signaling (Figure 9C).

Insulin stimulation of 3T3-L1 preadipocytes revealed 33% reduction in insulin receptor and reduced IGF 1R phosphorylation of Gpc4 knockdown cells compared to control (Figure 3A-B). The reduced IR/IGFIR activation resulted in a reduction of IRS-1 phosphorylation and a 40-45% reduction in ERK activation ($p< 0.01$) and phosphorylation of Akt on Ser473 ($p<0.001$) in Gpc4
20 knockdown cells (Figure 3C-D). This was not caused by reduced insulin binding, as shGpc4 preadipocytes showed higher binding of the ^{125}I insulin tracer, but lower affinity as judged by a rightward shift of the competition curve by unlabeled insulin (Figure 10A). Furthermore, AktS473 phosphorylation declined more rapidly in the Gpc4 knockdown cells during the 60 minute time course (Figure 3D) resulting in a ~50%> reduction of AktS473 phosphorylation over the time
25 course in Gpc4 knockdown cells as quantified by the area under the curve (Figure 3E). This decreased AktS473 and ERK phosphorylation in Gpc4 depleted cells was observed in a wide range of insulin concentrations (Figure 10B). However, these changes were specific to insulin and not observed after stimulation with 10% FBS (Figure IOC).

Gpc4 interacts with the insulin receptor and enhances adipocyte differentiation independent
30 **of membrane anchorage**

Gpc4 does not possess transmembrane or intracellular domains but is anchored to the cell membrane via a GPI anchor. Thus, Gpc4 itself cannot signal, but mediates its intracellular functions via interaction with other transmembrane proteins. Since depletion of Gpc4 resulted in

reduced insulin/IGF1 receptor activation (Figure 3A-B) a possible interaction of Gpc4 was tested for with these receptors by performing co-immunoprecipitation experiments. This revealed co-immunoprecipitation of Gpc4 with the insulin receptor under basal growth conditions, which was lost upon insulin stimulation, indicating that Gpc4 interacts with the unoccupied insulin receptor, but dissociates upon insulin binding and receptor activation. Interestingly, interaction with the IGF1R showed a reciprocal pattern, as Gpc4 associated with the IGF1R after, but not prior to, insulin stimulation (Figure 3F).

White adipose tissue is an endocrine organ secreting various adipokines, regulating metabolic function and glucose homeostasis (5). Glypicans can be released from the cell surface by cleavage of the GPI anchor (17). To determine if Gpc4 is released from adipocytes and acts as a soluble modulator of insulin signaling, 3T3-L1 cell lines were created with stable overexpression of native Gpc4 and a soluble mutant form of Gpc4 lacking the GPI anchor attachment site (AGpc4). Western blots confirmed moderate overexpression of native Gpc4 and AGpc4 (Figure 4A). Analysis of conditioned medium confirmed Gpc4 protein in the medium of AGpc4 cells, as well as smaller amounts of Gpc4 in the medium of control and cells overexpressing wild-type Gpc4, demonstrating that endogenous Gpc4 is released from the cell surface to the medium (Figure 4B). Overexpression of Gpc4 or AGpc4 opposed the results of Gpc4 depletion during adipocyte differentiation with slightly increased Ppary and C/EBPa expression and C/EBPβ phosphorylation compared to control cells (Figure 11A-B). This led to an increased adipocyte differentiation when compared to control cells (Figure 4C). Interestingly, overexpression of AGpc4 also resulted in enhanced adipocyte differentiation indicating that membrane anchorage is not required for the pro-adipogenic effect of Gpc4. Expression of perilipin and Glut4, both markers of mature adipocytes, were also significantly increased after differentiation of AGpc4 cells and trended towards being increased expression in Gpc4 overexpressing cells (Figure 4D).

To determine if soluble AGpc4 could interact with the insulin receptor, His-tagged-AGpc4 pulled-down using Ni-NTA agarose from cell lysates with or without insulin stimulation (Figure 4E). Similarly to endogenous membrane-anchored Gpc4, the insulin receptor co-precipitated with AGpc4 under basal conditions, but this interaction was lost upon insulin stimulation. Interestingly, AGpc4 was not pulled-down after insulin stimulation, indicating that not only is Gpc4 binding to the insulin receptor abolished upon insulin stimulation, but the sequestration of AGpc4 to the cell surface is lost.

Depletion of Gpc4 resulted in reduced insulin signaling. Overexpression of native Gpc4 or AGpc4 enhanced insulin-stimulated ERK (100% and 67%, respectively) and Akt-Ser473 (140%

and 94%, respectively) peak phosphorylation (Figure 4F) and Gpc4 increased 2-deoxy glucose uptake by cells (Figure 11C). Furthermore when 3T3-L1 cells were pretreated with affinity purified Gpc4 or control eluate during serum starvation (Figure 4G), Gpc4 enhanced ERK, Akt and IRS-1Y896 phosphorylation, after stimulation with insulin (Figure 4H).

5 **Gpc4 is released from adipose tissue and is a circulating marker for BMI and insulin resistance**

To determine if Gpc4 can be released from adipocytes into the circulation adipocytes were separated from the SVF of subcutaneous, perigonadal and brown fat, cultured them in *vitro,* and assayed the media for Gpc4 by Western blotting. The release of Gpc4 from intra-abdominal
10 (perigonadal) adipocytes was greater than that of subcutaneous adipocytes, and there was no release from either SVF or brown adipocytes (Figure 5A). Gpc4 mRNA expression was also significantly higher in isolated perigonadal adipocytes compared to the corresponding SVF (Figure 12). To determine if Gpc4 is also released in vivo, glycoproteins were purified from mouse serum and assayed these samples by Western blotting for Gpc4. As shown in Figure 5B, Gpc4 was
15 detected in sera from both male and female C57BL/6 mice. Mass spectrometric analysis confirmed this with three tryptic peptides for Gpc4 (Figure 13A). ELISA assays for Gpc4 revealed circulating levels of around 2ng/ml in lean C57B1/6 and ob/+ mice, which increased to ~4 ng/ml in mice subjected to eight weeks of HFD feeding, mirroring the gene expression data. Serum Gpc4 levels were ~lng/ml in the markedly obese ob/ob mice (Figure 5C). Fed blood glucose and insulin
20 measurements revealed that HFD fed mice were still able to maintain normal glycemia and normal insulinemia, with much higher serum Gpc4 levels than controls, whereas ob/ob mice had elevated blood glucose levels despite hyperinsulinemia, which was accompanied with reduced serum Gpc4 levels (Figure 13B).

To determine if Gpc4 was circulating in humans, a human Gpc4 ELISA assay was utilized
25 to assess serum Gpc4 levels in the same cohort that had been used for expression analysis of Gpc4 mRNA in adipose. In males serum Gpc4 levels paralleled the gene expression data from visceral fat (Figure 5D), with the highest serum Gpc4 levels in individuals who were overweight with a visceral distribution and lower levels in both lean and viscerally obese subjects. By contrast, females showed a continuous increase in serum Gpc4 levels from lean to overweight and obese.
30 When both male and female subjects were divided into the lowest and highest quartile of serum Gpc4 levels, those individuals with highest serum Gpc4 had significantly higher percentage body fat, higher BMI, larger WHR and higher levels of free fatty acids and leptin, all markers of body fat content. Additionally, high serum Gpc4 was associated increased markers of insulin resistance,

including high HOMA-IR, high fasting plasma insulin and insulin resistance as assessed by decreased GIR (Figure 5E and Figure 13C). Association was not observed with fasting-plasma-glucose, cholesterol, HDL-C, LDL-C or serum adiponectin, although in this group of non-diabetics, those with high serum Gpc4 did have significantly higher HbAlc values, although still within the normal range (Figure 13C). Multivariate analysis of 15 parameters including Gpc4 expression in subcutaneous and visceral fat confirmed a positive correlation of BMI and a negative correlation of GIR with serum Gpc4 levels (Table2 and Figure 14A). When subjects were divided into subgroups of non-obese and obese subjects with either low serum Gpc4 (<=5ng/ml) or high serum Gpc4 (>=9ng/ml), non-obese subjects with high serum Gpc4 levels showed the same degree of insulin resistance, measured by fasting plasma insulin, GIR and HOMA-IR, as obese subjects with either low or high serum Gpc4 levels (Figure 5F and Figure 14B). In an independent set of 30 age-, gender- and BMI- matched obese insulin sensitive and insulin resistant patients (18), ~2 times higher sGpc4 levels was observed in insulin resistant compared to insulin sensitive patients (Figure 5G).

Blunted Insulin Secretion in Glypican-4 Knockout Mice

Further, to test insulin secretion from pancreatic beta cells, Glypican-4 wild type and knockout mice were intraperitoneally injected with a bolus of glucose or 1-arginine and serum insulin levels measured at 2', 5' 10' and 15' post injection. Glypican-4 knockout animals had a blunted insulin secretion upon glucose injection, but not upon administration of 1-arginine, indicating that Glypican-4 knockout beta cells are (i) generally capable to secrete insulin, but show a specific glucose sensing defect. These data indicate that Glypican-4 not only modulates insulin receptor affinity and is a serum marker for insulin resistance, as shown in the previous publication, but also regulates the secretion of insulin from pancreatic beta cells. See, Figure 7.

Discussion

Glypican-4 belongs to the family of GPI-anchored heparan sulfate proteoglycans, which includes six members in mammals (10). It was previously found that Gpc4 is differentially expressed between fat depots and is highly regulated in obesity (8). The present invention shows that Gpc4 regulates insulin signaling via interaction with the insulin receptor. As a result, reducing levels of Gpc4 diminishes insulin signaling. In preadipocytes, this results in blunted activation of C/EBPβ and a block in adipocyte differentiation. The present invention also demonstrates that Gpc4 is released from adipose tissue and that circulating Gpc4 in rodents and humans positively correlates with body fat content and insulin resistance.

Expansion of visceral adipose tissue, i.e., central obesity, is associated with insulin resistance, whereas expansion of subcutaneous adipose tissue, i.e., peripheral obesity, is not (7, 5). Defining the mechanisms underlying body fat distribution and this differential link to insulin resistance is important for understanding the development of comorbidities associated with obesity, including type 2 diabetes, stroke, hypertension and cardiovascular disease (19). The present invention shows that expression of Gpc4 is not only differential between subcutaneous and visceral fat, but that Gpc4 expression in visceral adipose positively correlates with both BMI and, independently, with insulin resistance as measured by euglycemic, hyperinsulinemic clamps. Of greater significance, Gpc4 is present in serum of mice and humans, and serum Gpc4 levels are positively correlated with body fat content and insulin resistance. In non-diabetics, serum Gpc4 increases progressively with BMI, especially in viscerally obese women and viscerally overweight males. Multivariate analysis revealed an independent negative correlation of serum Gpc4 with GIR, i.e., thus higher serum Gpc4 levels are associated with greater insulin resistance. Indeed, non-obese subjects (BMK30) with high serum Gpc4 (>9ng/ml) levels have the same degree of insulin resistance by euglycemic clamp, fasting insulin and HOMA-IR as obese subjects, independent of serum Gpc4 levels. Furthermore sGpc4 levels are doubled in insulin resistant obese subjects compared to age-, gender- and BMI- matched insulin sensitive subjects. Thus serum Gpc4 is not only a marker for BMI, it is an independent marker of insulin resistance.

This link between Gpc4 and changes in insulin sensitivity appears to involve two novel mechanisms. First, glypicans are released from the cell surface by an enzymatically regulated process mediated by GPI-lipases. Glycosylphosphatidylinositol-specific phospholipase D (GPLDl) has been suggested to cleave Gpc4 (17, 20) and its activity is regulated by insulin (21 ,22). Similar to Gpc4, GPLDl levels in serum are increased upon feeding a high sucrose diet (23), but decreased in ob/ob mice (24). This could explain the lack of direct correlation between expression of Gpc4 in fat and serum Gpc4 levels. The present invention did not find change in Gpldl expression in adipose tissue of ob/ob mice, but another GPI lipase, Notum, increased (Figure 15). In addition Gpc4 is widely expressed with highest expression in kidney, pituitary and white adipose tissue, indicating that other tissues could contribute to serum Gpc4.

However the strong association of serum Gpc4 levels with BMI in humans and the fact that Gpc4 can be released from cultured primary adipocytes make adipose tissue one likely source of serum Gpc4.

To date, no circulating factor has been shown to directly enhance the activation of the insulin receptor itself. Both the transmembrane glycoprotein PC-l/ENPP-1 and circulating alpha 2-HS glycoprotein are known to interact with the extracellular domains of the insulin receptor and to negatively affect insulin binding and activation of the insulin receptor (25, 26). By contrast, it was shown that both membrane and non-membrane bound Gpc4 can interact with the insulin receptor and enhance insulin signaling. This interaction occurs with the unoccupied insulin receptor, and stimulation by insulin disrupts the interaction of Gpc4 with the insulin receptor. Thus, overexpression of native Gpc4 or AGpc4 or addition of recombinant AGpc4 enhances insulin signaling in 3T3-L1 cells, whereas the depletion of Gpc4 results in reduced insulin receptor phosphorylation and downstream signaling.

Insulin is an important regulator of adipocyte differentiation and function (4). In line with that adipocyte differentiation is increased in Gpc4 or AGpc4 overexpressing cells and blocked in Gpc4 knockdown cells. The latter is due to an inability to induce C/EBPa and PPARy the key transcription factors required for differentiation, secondary to reduced phosphorylation of C/EBPβ at the ERK/GSK3p consensus site Thrl88. Phosphorylation of Thrl88 is essential for DNA binding and transactivation of C/EBPa and PPARy (16, 27). Block of adipocyte differentiation at this stage of differentiation is also seen in IRS-l/IRS-2 double knockout cells (28) further indicating a link between insulin signaling and the adipocyte differentiation defect. Overexpression of the Akt and ERK inhibitor TRB3 also prevents activation of C/EBPβ and thereby inhibits adipocyte differentiation (29). However, it is possible that Gpc4 could affect additional signaling pathways, or that other factors within the insulin signaling pathway contribute to the differentiation defect, as insulin signaling induces a variety of transcription factors that might regulate adipocyte differentiation (30).

Taken together our data show the novel and non-obvious finding that Gpc4 is an insulin-sensitizing "adipokine" that directly interacts with the insulin receptor to regulate its activation and downstream signaling. The importance of Gpc4 in modulating insulin signaling is underlined by the inability of Gpc4 knockdown cells to differentiate into adipocytes due to a lack of insulin signaling. In addition to its biological activity, serum levels of Gpc4 are correlated with insulin resistance. The role of Gpc4 as an insulin sensitizer and its higher serum levels in insulin resistant individuals may seem counterintuitive at first. However insulin itself shows a similar distribution with lower levels in insulin sensitive versus insulin resistant individuals. Given that GPLD1 is the most likely candidate to cleave Gpc4 and is itself an insulin regulated gene, it is possible that increasing levels of insulin early in obesity lead to increased Gpc4 cleavage resulting in increased circulating Gpc4 levels. With disease progression, as in the ob/ob mouse, increased insulin resistance in GPLD1-producing cells would result in a reduction of GPLD1 activity and a drop in circulating Gpc4 levels, further decreasing insulin sensitivity and

accelerating disease progression. Thus, our data suggest that increased circulating Gpc4 levels could be a novel regulatory mechanism by which fat acts to counteract insulin resistance, and maintaining high serum Gpc4 levels in severely insulin resistant or diabetic subjects could lower insulin demands. While further studies will be required to dissect the various function of soluble vs. membrane bound Gpc4, glypican-4 forms a novel adipokine and a novel mechanism by which adipose tissue can modulate insulin signaling.

Equivalents

Those skilled in the art will recognize, or be able to ascertain and implement using no more than routine experimentation, many equivalents of the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims. Any combinations of the embodiments disclosed in the dependent claims are contemplated to be within the scope of the disclosure.

Incorporation by reference

The disclosure of each and every US and foreign patent and pending patent application and all publications referred to herein (including in the attached manuscript) are specifically incorporated by reference herein in their entirety.

Reference List

1. S. Gesta, Y. H. Tseng, and C. R. Kahn Developmental origin of fat: tracking obesity to its source *Cell.* 131, 242-256 (10-19-2007)

2. T. T. Tran, Y. Yamamoto, S. Gesta, and C. R. Kahn Beneficial effects of subcutaneous fat transplantation on metabolism *Cell Metab.* 7, 410-420 (2008)

3. S. C. Butterwith Regulators of adipocyte precursor cells *Poult.Sci.* 76, 118-123 (1997)

4. M. Bluher, M. D. Michael, O. D. Peroni, K. Ueki, N. Carter, B. B. Kahn, and C. R. Kahn Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance *Dev Cell.* 3, 25-38 (2002)

5. Y. Deng and P. E. Scherer Adipokines as novel biomarkers and regulators of the metabolic syndrome *Ann N YAcad Sci.* 1212, E1-E19 (2010)

6. R. S. Ahima and J. S. Flier Adipose tissue as an endocrine organ *Trends Endocrinol Metab.* 11, 327-332 (2000)

7. S. Kralisch, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome *Mini. Rev Med Chem.* 7, 39-45 (2007)

8. S. Gesta, M. Bluher, Y. Yamamoto, A. W. Norris, J. Berndt, S. Kralisch, J. Boucher, C. Lewis, and C. R. Kahn Evidence for a role of developmental genes in the origin of obesity and body fat distribution *Proc Natl Acad Sci U S.A.* 103, 6676-6681 (4-25-2006)

9. B. De Cat and G. David Developmental roles of the glypicans *Semin. Cell Dev Biol.* 12, 117-125 (2001)

10. A. Fico, F. Maina, and R. Dono Fine-tuning of cell signaling by glypicans *Cell Mol Life Sci.* 68, 923-929 (2011)

11. J. Filmus, M. Capurro, and J. Rast Glypicans *Genome Biol.* 9, 224-2008)

12. S. A. Karumanchi, V. Jha, R. Ramchandran, A. Karihaloo, L. Tsiokas, B. Chan, M. Dhanabal, J. I. Hanai, G. Venkataraman, Z. Shriver, N. Keiser, R. Kalluri, H. Zeng, D. Mukhopadhyay, R. L. Chen, A. D. Lander, K. Hagihara, Y. Yamaguchi, R. Sasisekharan, L. Cantley, and V. P. Sukhatme Cell surface glypicans are low-affinity endostatin receptors *Mol Cell. 7,* 811-822 (2001)

13. K. Hagihara, K. Watanabe, J. Chun, and Y. Yamaguchi Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells *Dev.Dyn.* 219, 353-367 (2000)

14. S. R. Farmer Transcriptional control of adipocyte formation *Cell Metab.* 4, 263-273 (2006)

15. Y. Y. Zhang, X. Li, S. W. Qian, L. Guo, H. Y. Huang, Q. He, Y. Liu, C. G. Ma, and Q. Q. Tang Transcriptional activation of histone H4 by C/EBP{beta} during the mitotic clonal expansion of 3T3-L1 adipocyte differentiation *Mol Biol Cell.* 22, 2165-2174 (2011)

16. B. H. Park, L. Qiang, and S. R. Farmer Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes *Mol Cell Biol.* 24, 8671-

8680 (2004)

17. A. Traister, W. Shi, and J. Filmus Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface *Biochem.J.* 10-30-2007)

18. N. Kloting, M. Fasshauer, A. Dietrich, P. Kovacs, M. R. Schon, M. Kern, M. Stumvoll, and M. Bluher Insulin-sensitive obesity *AmJ. Physiol Endocrinol. Metab.* **299,** E506-E515 (2010)

19. S. M. Grundy Obesity, metabolic syndrome, and cardiovascular disease *J Clin Endocrinol Metab.* **89,** 2595-2600 (2004)

20. G. Brunner, C. N. Metz, H. Nguyen, J. Gabrilove, S. R. Patel, M. A. Davitz, D. B. Rifkin, and E. L. Wilson An endogenous glycosylphosphatidylinositol-specific phospholipase D releases basic fibroblast growth factor-heparan sulfate proteoglycan complexes from human bone marrow cultures *Blood.* **83,** 2115-2125 (4-15-1994)

21. N. S. Raikwar, R. F. Bowen-Deeg, X. S. Du, M. G. Low, and M. A. Deeg Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance *Metabolism.* **59,** 1413-1420 (2010)

22. A. R. Saltiel and P. Cuatrecasas In search of a second messenger for insulin *Am J Physiol.* **255,** Cl-11 (1988)

23. T. A. Kurtz, N. S. Fineberg, R. V. Considine, and M. A. Deeg Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D *Metabolism.* **53,** 138-139 (2004)

24. R. F. Bowen, N. S. Raikwar, L. K. Olson, and M. A. Deeg Glucose and insulin regulate glycosylphosphatidylinositol-specific phospholipase D expression in islet beta cells *Metabolism.* **50,** 1489-1492 (2001)

25. J. F. Youngren Regulation of insulin receptor function *Cell Mol Life Sci.* **64,** 873-891 (2007)

26. P. R. Srinivas, A. S. Wagner, L. V. Reddy, D. D. Deutsch, M. A. Leon, A. S. Goustin, and G. Grunberger Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level *Mol. Endocrinol.* **7,** 1445-1455 (1993)

27. Q. Q. Tang, M. Gronborg, H. Huang, J. W. Kim, T. C. Otto, A. Pandey, and M. D. Lane Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis *Proc Natl Acad Sci U S.A.* **102,** 9766-9771 (7-12-2005)

28. H. Miki, T. Yamauchi, R. Suzuki, K. Komeda, A. Tsuchida, N. Kubota, Y. Terauchi, J. Kamon, Y. Kaburagi, J. Matsui, Y. Akanuma, R. Nagai, S. Kimura, K. Tobe, and T. Kadowaki Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation *Mol Cell Biol.* **21,** 2521-2532 (2001)

29. O. Bezy, C. Vernochet, S. Gesta, S. R. Farmer, and C. R. Kahn TRB3 blocks adipocyte differentiation through the inhibition of C/EBPbeta transcriptional activity *Mol Cell Biol.* **27,** 6818-6831 (2007)

30. J. Boucher, Y. H. Tseng, and C. R. Kahn Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription *J Biol Chem.* **285,** 17235-17245 (5-28-2010)

31. A. Woods and J. R. Couchman Proteoglycan isolation and analysis *Curr.Protoc.Cell Biol.* **Chapter 10,** Unit-2001)

32. C. Grunfeld, O. E. Van, F. A. Karlsson, and C. R. Kahn Antibody-induced desensitization of the insulin receptor. Studies of the mechanism of desensitization in 3T3-L1 fatty fibroblasts *J.Clin. Invest.* 66, 1124-1134 (1980)

Table 1: Multivariate regression analysis of Gpc4 WAT expression with clinical parameters

	Gpc4-SCF	Gpc4-Visc
Gpc4-SCF/Visc	**-0.446 ± 0.124**	**-0.183 ± 0.051**
GIR	0.301 ± 0.167	**-0.367 ± 0.104**
FPG	-2.99 ± 10.453	-2.754 ± 6.691
FPI	-0.294 ± 0.454	0.093 ± 0.291
HOMA-IR	8.277 ± 12.882	-3.807 ± 8.254
HbA1c	-14.145 ± 12.424	2.03 ± 7.989
WHR	**-67.304 ± 26.343**	23.974 ± 17.128
BMI	-0.821 ± 0.668	0.707 ± 0.426
FFA	3.226 ± 11.273	4.479 ± 7.211
Cholesterol	-3.451 ± 5.653	-1.742 ± 3.622
HDL-C	10.937 ± 9.864	-0.797 ± 6.343
LDL-C	-5.614 ± 5.092	-0.916 ± 3.273
Gender	-10.416 ± 6.786	2.889 ± 4.374
Age	0.34 ± 0.201	-0.44 ± 0.128

Shown are correlation coefficients ± standard error. Values highlighted in bold indicate significant correlations with a p-value <0.05. SCF: subcutaneous fat; Vise: visceral fat.

Table 2: Multivariate regression analysis of serum Gpc4 with clinical parameters and Gpc4 expression in WAT

	serum Gpc4
Gpc4-SCF	0.004 ± 0.009
Gpc4-Visc	-0.21 ± 0.014
GIR	**-0.46 ± 0.019**
FPG	-0.002 ± 1.164
FPI	0.0004788 ± 0.0515
HOMA-IR	-0.59 ± 1.436
HbA1c	0.585 ± 1.389
WHR	3.023 ± 2.998
BMI	**0.179 ± 0.075**
FFA	0.895 ± 1.255
Cholesterol	0.217 ± 0.63
HDL-C	0.518 ± 1.103
LDL-C	-0.996 ± -0.569
Gender	1.434 ± 0.762
Age	0.002 ± 0.022

Shown are correlation coefficients ± standard error. Values highlighted in bold indicate significant correlations with a p-value <0.05. SCF: subcutaneous fat; Vise: visceral fat.

Supplementary Table 1. Shown are clinical parameters for female and male subjects, divided by BMI and body fat distribution used to measure adipose Gpc4 mRNA expression and serum Gpc4 levels. vise. BMI 25-30 and vise. BMI >30 indicates subjects with a CT or MRI ratio between subcutaneous and visceral fat areas >0.4 in the given BMI range.

Female										
Group	BMI <25		BMI 25-30		Visc. BMI 25-30		BMI >30		Visc. BMI >30	
BMI (kg/m²)	23.3	±1.1	27.7	±1.6	27.1	±1.0	36.0	±4.9	37.4	±5.7
WHR	0.7	±0.1	0.9	±0.1	1.0	±0.1	1.0	±0.2	1.2	±0.1
% body fat	21.7	±2.8	30.6	±6.2	26.5	±3.2	40.2	±6.9	36.0	±7.9
FPG (mmol/l)	5.3	±0.4	5.3	±0.6	5.1	±0.6	5.4	±0.4	5.4	±0.3
FPI (pmol/l)	27.5	±12.6	97.0	±65.6	74.3	±16.1	153.0	±95.4	152.9	±78.8
Clamp GIR (µmol/kg/min)	97.4	±10.5	59.1	±25.3	54.3	±24.9	53.9	±24.1	47.6	±33.7
HbA1c (%)	5.3	±0.2	5.4	±0.2	5.6	±0.2	5.5	±0.3	5.5	±0.3
Cholesterol (mmol/l)	5.0	±0.8	4.7	±0.6	5.4	±0.5	4.9	±0.7	5.7	±0.7
HDL-C (mmol/l)	1.5	±0.4	1.3	±0.4	1.6	±0.5	1.4	±0.4	1.6	±0.3
LDL-C (mmol/l)	2.9	±0.9	2.6	±0.5	3.5	±0.5	2.7	±0.6	3.4	±0.5
FFA (mmol/l)	0.3	±0.1	0.4	±0.3	0.6	±0.1	0.6	±0.4	0.9	±0.2
Leptin (ng/ml)	8.7	±4.3	26.8	±10.8	35.6	±15.4	33.0	±11.2	31.5	±7.9
Adiponectin (ng/ml)	9.7	±4.5	8.4	±5.1	3.4	±1.9	7.4	±4.3	5.9	±3.3
Male										
Group	BMI <25		BMI 25-30		Visc. BMI 25-30		BMI >30		Visc. BMI >30	
BMI (kg/m²)	23.9	±0.9	26.8	±1.7	28.0	±1.3	37.1	±5.0	35.9	±5.7
WHR	0.9	±0.1	1.0	±0.1	1.1	±0.1	1.1	±0.1	1.2	±0.1
% body fat	21.3	±2.7	26.6	±6.7	30.3	±3.3	42.5	±8.8	34.5	±5.8
FPG (mmol/l)	5.4	±0.4	5.4	±0.5	5.2	±0.4	5.4	±0.5	5.5	±0.5
FPI (pmol/l)	31.5	±14.9	72.7	±90.6	203.5	±81.4	146.0	±113.9	128.8	±56.3
Clamp GIR (µmol/kg/min)	96.8	±5.5	85.6	±24.1	30.8	±12.9	59.0	±26.2	47.3	±31.1
HbA1c (%)	5.3	±0.2	5.4	±0.3	5.6	±0.2	5.6	±0.2	5.6	±0.3
Cholesterol (mmol/l)	5.1	±0.8	4.8	±0.7	5.6	±0.5	4.8	±0.5	5.5	±1.0
HDL-C (mmol/l)	1.4	±0.4	1.4	±0.3	1.8	±0.4	1.3	±0.3	1.4	±0.2
LDL-C (mmol/l)	2.7	±0.7	2.5	±0.5	3.1	±0.4	2.7	±0.6	3.6	±1.1
FFA (mmol/l)	0.3	±0.2	0.4	±0.2	0.7	±0.3	0.6	±0.4	0.7	±0.4
Leptin (ng/ml)	3.2	±2.9	9.6	±11.8	22.1	±9.7	19.3	±8.3	16.6	±9.9
Adiponectin (ng/ml)	9.7	±2.5	9.2	±6.7	4.3	±3.6	6.1	±2.6	4.3	±2.0

CLAIMS:

1. A method for increasing insulin sensitivity in a subject, comprising administering to a subject in need of increased insulin sensitivity a therapeutically effective amount of a glypican-4 agent.

2. The method of claim 1, wherein the subject is insulin resistant.

3. The method of claim 1, wherein the subject has metabolic syndrome.

4. The method of claim 1, wherein the subject has type 2 diabetes.

5. The method of claim 1, wherein the glypican-4 agent is a human glypican-4 protein or a biologically active fragment thereof.

6. The method of claim 5, wherein the human glypican-4 protein or biologically active fragment thereof comprises a GPI anchor.

7. The method of claim 5, wherein the human glypican-4 protein or biologically active fragment thereof is a soluble protein.

8. The method of claim 1, wherein the glypican-4 agent is administered systemically.

9. The method of claim 1, wherein the glypican-4 agent is administered into adipose tissue.

10. A pharmaceutical composition comprising a glypican-4 agent that increases sensitivity to insulin and a pharmaceutically acceptable vehicle.

11. A method for determining whether a subject is or is likely to become insulin resistant, comprising providing a serum sample of the subject; and determining the level of glypican-4 in the serum sample, wherein a level of glypican-4 that is $\geq$ 9 ng/ml indicates that the subject has or is likely to become insulin resistant.

12. The method of claim 11, wherein the subject is not obese (BMI $<$ 30).

13. A method for determining whether a treatment for insulin resistance is effective in a subject, comprising

providing a sample of serum from a subject receiving a treatment for insulin resistance; and

determining the level of glypican-4 in the serum sample, wherein a lower level of glypican-4 in the serum sample relative to that in a serum sample obtained earlier during the treatment or before the treatment indicates that the treatment is effective, whereas a similar or higher level of

glypican-4 in the serum sample relative to that in a serum sample obtained earlier during the treatment or before the treatment indicates that the treatment is not effective.

14. The method of claim 13, wherein the treatment for insulin resistance is administration of a glypican-4 agent, and the method comprises measuring the level of naturally occurring glypican-4.

15. The method of claim 13, further comprising adjusting the treatment if the level of glypican-4 is similar or higher to that in a serum sample of the subject at an earlier time during the treatment or prior to the treatment.

16. A method of identifying an agent that increases the sensitivity of a subject to insulin, comprising

contacting a glypican-4 protein or a biologically active fragment thereof with an insulin receptor in the presence of a test compound; and

determining the level of interaction of the glypican-4 protein and the insulin receptor in the presence of a test compound, wherein a weaker interaction in the presence of the test compound indicates that the test compound is an agent that increases the sensitivity of a subject to insulin.

17. The method of claim 16, wherein the insulin receptor is on the surface of a cell.

18. The method of claim 17, wherein the insulin receptor is on the surface of an adipose cell.

19. An isolated complex comprising a glypican-4 protein or biologically active fragment thereof and an insulin receptor or biologically active fragment thereof.

20. The isolated complex of claim 19, wherein the insulin receptor is on an adipose cell.

21. The isolated complex of claim 19, wherein the glypican-4 protein or biologically active fragment thereof is on an adipose cell.

22. A composition comprising the isolated complex of claim 19 and a test compound.

Figure 1



Figure 2



Figure 3



Figure 4



Figure 5



Human Glypican-4 precursor protein:

```
  1 MARFGLPALL CTLAVLSAAL LAAELKSKSC SEVRRLYVSK GFNKNDAPLH EINGDHLKIC
 61 PQGSTCCSQE MEEKYSLQSK DDFKSVVSEQ CNHLQAVFAS RYKKFDEFFK ELLENAEKSL
121 NDMFVKTYGH LYMQNSELFK DLFVELKRYY VVGNVNLEEM LNDFWARLLE RMFRLVNSQY
181 HFTDEYLECV SKYTEQLKPF GDVPRKLKLQ VTRAFVAART FAQGLAVAGD VVSKVSVVNP
241 TAQCTHALLK MIYCSHCRGL VTVKPCYNYC SNIMRGCLAN QGDLDFEWNN FIDAMLMVAE
301 RLEGPFNIES VMDPIDVKIS DAIMNMQDNS VQVSQKVFQG CGPPKPLPAG RISRSISESA
361 FSARFRPHHP EERPTTAAGT SLDRLVTDVK EKLKQAKKFW SSLPSNVCND ERMAAGNGNE
421 DDCWNGKGKS RYLFAVTGNG LANQGNNPEV QVDTSKPDIL ILRQIMALRV MTSKMKNAYN
481 GNDVDFFDIS DESSGEGSGS GCEYQQCPSE FDYNATDHAG KSANEKADSA GVRPGAQAYL
541 LTVFCILFLV MQREW     (SEQ ID NO: 2)
```

Mature human Glypican-4 protein:

```
  1 AELKSKSCSE VRRLYVSKGF NKNDAPLHEI NGDHLKICPQ GSTCCSQEME EKYSLQSKDD
 61 FKSVVSEQCN HLQAVFASRY KKFDEFFKEL LENAEKSLND MFVKTYGHLY MQNSELFKDL
121 FVELKRYYVV GNVNLEEMLN DFWARLLERM FRLVNSQYHF TDEYLECVSK YTEQLKPFGD
181 VPRKLKLQVT RAFVAARTFA QGLAVAGDVV SKVSVVNPTA QCTHALLKMI YCSHCRGLVT
241 YCSHCRGLVT VKPCYNYCSN IMRGCLANQG DLDFEWNNFI DAMLMVAERL EGPFNIESVM
301 DPIDVKISDA IMNMQDNSVQ VSQKVFQGCG PPKPLPAGRI SRSISESAFS ARFRPHHPEE
361 RPTTAAGTSL DRLVTDVKEK LKQAKKFWSS LPSNVCNDER MAAGNGNEDD CWNGKGKSRY
421 LFAVTGNGLA NQGNNPEVQV DTSKPDILIL RQIMALRVMT SKMKNAYNGN DVDFFDISDE
481 SSGEGSGSGC EYQQCPSEFD YNATDHAGKS ANEKADSAGV RPGAQAYLLT VFCILFLVMQ
541 REW     (SEQ ID NO: 3)
```

FIGURE 6

{W3478462.1}

Nucleotide sequence encoding the human glypican-4 precursor protein of SEQ ID NO: 2:

```
   1 gcctggcacc ggggaccgtt gcctgacgcg aggcccagct ctacttttcg ccccgcgtct
  61 cctccgcctg ctcgcctctt ccaccaactc caactccttc tccctccagc tccactcgct
 121 agtccccgac tccgccagcc ctcggcccgc tgccgtagcg ccgcttcccg tccggtccca
 181 aaggtgggaa cgcgtccgcc ccggcccgca ccatggcacg gttcggcttg cccgcgcttc
 241 tctgcaccct ggcagtgctc agcgccgcgc tgctggctgc cgagctcaag tcgaaaagtt
 301 gctcggaagt gcgacgtctt tacgtgtcca aaggcttcaa caagaacgat gccccccctcc
 361 acgagatcaa cggtgatcat ttgaagatct gtccccaggg ttctacctgc tgctctcaag
 421 agatggagga gaagtacagc ctgcaaagta aagatgattt caaaagtgtg gtcagcgaac
 481 agtgcaatca tttgcaagct gtctttgctt cacgttacaa gaagtttgat gaattcttca
 541 aagaactact tgaaaatgca gagaaatccc tgaatgatat gtttgtgaag acatatggcc
 601 atttatacat gcaaaattct gagctattta aagatctctt cgtagagttg aaacgttact
 661 acgtggtggg aaatgtgaac ctggaagaaa tgctaaatga cttctgggct cgcctcctgg
 721 agcggatgtt ccgcctggtg aactcccagt accactttac agatgagtat ctggaatgtg
 781 tgagcaagta tacggagcag ctgaagccct tcggagatgt ccctcgcaaa ttgaagctcc
 841 aggttactcg tgcttttgta gcagcccgta ctttcgctca aggcttagcg gttgcgggag
 901 atgtcgtgag caaggtctcc gtggtaaacc ccacagccca gtgtacccat gccctgttga
 961 agatgatcta ctgctcccac tgccggggtc tcgtgactgt gaagccatgt tacaactact
1021 gctcaaacat catgagaggc tgtttggcca accaagggga tctcgatttt gaatggaaca
1081 atttcataga tgctatgctg atggtggcag agaggctaga gggtcctttc aacattgaat
1141 cggtcatgga tcccatcgat gtgaagattt ctgatgctat tatgaacatg caggataata
1201 gtgttcaagt gtctcagaag gttttccagg gatgtggacc ccccaagccc ctcccagctg
1261 gacgaatttc tcgttccatc tctgaaagtg ccttcagtgc tcgcttcaga ccacatcacc
1321 ccgaggaacg cccaaccaca gcagctggca ctagtttgga ccgactggtt actgatgtca
```

FIGURE 6 (Continued)

```
1381 aggagaaact gaaacaggcc aagaaattct ggtcctccct tccgagcaac gtttgcaacg
1441 atgagaggat ggctgcagga aacggcaatg aggatgactg ttggaatggg aaaggcaaaa
1501 gcaggtacct gtttgcagtg acaggaaatg gattagccaa ccagggcaac aacccagagg
1561 tccaggttga caccagcaaa ccagacatac tgatccttcg tcaaatcatg gctcttcgag
1621 tgatgaccag caagatgaag aatgcataca atgggaacga cgtggacttc tttgatatca
1681 gtgatgaaag tagtggagaa ggaagtggaa gtggctgtga gtatcagcag tgcccttcag
1741 agtttgacta caatgccact gaccatgctg ggaagagtgc caatgagaaa gccgacagtg
1801 ctggtgtccg tcctgggca caggcctacc tcctcactgt cttctgcatc ttgttcctgg
1861 ttatgcagag agagtggaga taattctcaa actctgagaa aaagtgttca tcaaaaagtt
1921 aaaaggcacc agttatcact tttctaccat cctagtgact ttgcttttta aatgaatgga
1981 caacaatgta cagtttttac tatgtggcca ctggtttaag aagtgctgac tttgttttct
2041 cattcagttt tgggaggaaa agggactgtg cattgagttg gttcctgctc ccccaaacca
2101 tgttaaacgt ggctaacagt gtaggtacag aactatagtt agttgtgcat ttgtgatttt
2161 atcactctat tatttgtttg tatgtttttt tctcatttcg tttgtgggtt tttttttcca
2221 actgtgatct cgccttgttt cttacaagca aaccagggtc ccttcttggc acgtaacatg
2281 tacgtatttc tgaaatatta aatagctgta cagaagcagg ttttatttat catgttatct
2341 tattaaaaga aaaagcccaa aaagcagtaa aatttccatt tctccctgtt attttagttg
2401 ccttatctgg agagacgtgg aggtgatttt ctttttttta aattattatt aagacagaat
2461 gtgagggcac aagcaggctt ctgagccact tgtcagattg tattcaaagc atcaatccaa
2521 gaaggaggtt atgtgtactt catttattgg tgatagttgg aagagactgc agactactgc
2581 tttgaatgag ttgaattaca taagctaaga tcactatagg tccatttctt gaacccactt
2641 atacataaaa tgtaacccat ttagaaaaag attctggata tcatccccct tgaaagatag
2701 aaagcattca ggatgtccca gttatcacat gttcacactt gggtttaggg gtgttttttt
2761 ttaaaaccag gcaggttagc tagcccaccc tgtgctagtt ttcatgttca cactgaccct
2821 atttgaatta atatcctttg ttagagtggt cgagatttca aacccaatta tgtacaggga
2881 gctgtctgag agctagccag aactggggta cagcctgggc tcagggaata gctgtcaaca
2941 ctcgggcaaa gtttttgtct gtgcatgtgt atctccattt gttttgggat cccagttttt
3001 gttttaagag agtataaggt gtctcatttg agtctttttc ttacctagcc ccctcttatc
```

FIGURE 6 (Continued)

```
3061 agtaaaacaa aggacttgcc atggttcaca gcaatgtgct acgatccaag atatcagcca
3121 aggagcccac ttaggggaga actaggtgtc cagatttttg tatgtgttgt ttttcttggg
3181 ggatggggtg gggtgggagt aggtagagct gagaatacta catcttagtg gtgaccttta
3241 gccacgtggg tgaagtggca aaggccatgg ccatatctgt tgtcccaggc caaagactaa
3301 caactgcctt gggaatccct tccttgtgtc cttaccaaat gatagctcat aaaactctga
3361 taatgtaaca aatcactttc aaaggagttc ccagaagtct tcagaaagac taaaattctg
3421 tctcttcctg ctttagacag ccattaagat cccaactaat tttaccgaac ctaaaaccca
3481 caaagaggtt gtttgtgtta ttgttcaatc ttcagttgta agagtaattc tctattttta
3541 tattgaaaca taattacttg atagctcagg gtctacattt cattcaactt tttacaccaa
3601 attctgcaga gtggtcaaaa tggaatattg gggctgttg taaacagagg cttaatttta
3661 ttagaagtag ccagttattt attaaagcat gatgttaata aaataggcat attc
    (SEQ ID NO: 1)
```

FIGURE 6 (Continued)

Figure 7



Figure 8



Figure 9



Figure 10







Figure 11

A





C



Figure 12



Figure 13

A

*MARLGLLALLCTLAALSASLLA*AELKSKSCSEVRRLYVSKGFNKNDAPLYEINGDHLKICPQDYTCCSQE
MEEKYSLQSKDDFKTVVSEQCNHLQAIFASRYKKFDEFFKELLENAEKSLNDMFVKTYGHLYMQNSELF
KDLFVELKRYYVAGNVNLEEMLNDFWARLLERMFRLVNSQYHFTDEYLECVSKYTEQLKPFGDVPRKLKL
QVTRAFVAARTFAQGLAVAGDVVSKVSVVNPTAQCTHALLKMIYCSHCRGLVTVKPCYNYCSNIMRGCLA
NQGDLDFEWNNFIDAMLMVAERLEGPFNIESVMDPIDVKISDAIMNMQDNSVQVSQKVFQGCGPPKPLPA
G**RISR**SISESAFSARFRPYHPEQRPTTAAGTSLDRLVTDVKEKLKQAKKFWSSLPSTVCNDERMAAGNEN
EDDCWNGKGKSRYLFAVTGNGLANQGNNPEVQVDTSKPDILILRQIMALRVMTSKMKNAYNGNDVDFFDI
SDESSGEGSGSGCEYQQCPSEFEYNATDHSGKSANEKADSAGGAHAEAKPYLLAALCILFLAVQGEWR

* identified peptides by MassSpec
bold indicates potential cleavage site
italic indicates signal peptide

B



C



Figure 14



Figure 15



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2012/072310

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A61K 38/17 (2013.01)
USPC - 435/375
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC(8) - A61K 38/17, 38/28, 39/395, 47/30, 48/00; C07K 14/47; C12Q 1/68 (2013.01)
USPC - 435/6, 6.1, 6.13, 375; 514/1.1, 6.9, 12, 44; 530/324, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
CPC - A61K 38/16; C07K 14/705; C12N 15/1138; C12Q 1/6837, 2600/158 (2013.01)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Google Patents, Google, PubMed

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 2009/0203602 A1 (GELBER et al) 13 August 2009 (13.08.2009) entire document	1-4, 8-11 -------- 5-7, 12-15
X -- Y	US 2006/0121041 A1 (FRIEDMAN et al) 08 June 2006 (08.06.2006) entire document	19, 22 -------- 5-7, 20, 21
Y	US 2009/0220973 A1 (GESTA et al) 03 September 2009 (03.09.2009) entire document	12-15, 20, 21
A	US 2011/0111404 A1 (SALONEN et al) 12 May 2011 (12.05.2011) entire document	1-22
A	US2009/0298771 A1 (ONICHTCHOUK) 03 December 2009 (03.12.2009) entire document	1-22
A	GESTA et al. "Evidence for a role of developmental genes in the origin of obesity and body fat distribution," Proceedings of the National Academy of Sciences, 14 April 2006 (14.04.2006), Vol. 103, No. 17, Pgs. 6676-6681 . entire document	1-22
P	USSAR et al. "Glypican-4 Enhances Insulin Signaling via Interaction with the Insulin Receptor and Serves as a Novel Adipokine," Diabetes, 29 June 2012 (29.06.2012), Vol. 61, No. 9, Pgs. 2289-2298. entire document	1-22

☐ Further documents are listed in the continuation of Box C. ☐

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 March 2013	04 APR 2013

Name and mailing address of the ISA/US	Authorized officer:
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Blaine R. Copenheaver PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774